Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy Leukemia (2015) 29, 2421-2423; doi:10.1038/leu. 2015.151 Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) occur in~15-20% of patients with acute myeloid leukemia (AML). 1 A consequence is the aberrant accumulation of the (D)-enantiomer of 2-hydroxyglutarate (D-2-HG), a putative oncometabolite that competitively inhibits α-ketoglutarate-dependent epigenetic regulators such as TET2 and Jumonji domain histone demethylases. 2 The presence of elevated 2-HG (either total or more specifically the D-enantiomer) in plasma or serum accurately identifies AML patients with IDH1 or IDH2 mutations, and 2-HG levels mirror disease burden. [3] [4] [5] [6] However, it is not yet known whether 2-HG measurement represents the optimal approach to monitoring IDH mutant (IDH mut ) allele burden during and after therapy, or whether alternative strategies such as allele-specific digital PCR may be equivalent or superior. Indeed, an evaluation of digital PCR in IDHmutated AML has not yet been reported. Accurate assessment of mutant allele burden is essential to guide therapy and to predict prognosis, the more so given recent promising results from early phase trials of selective IDH mut inhibitors. 7 To address this question, we have developed an allele-specific digital PCR method for recurring IDH1 and IDH2 mutations in AML, and made a direct comparison with 2-HG D:L enantiomeric ratios in concomitantly collected plasma samples. The 2-HG D:L ratio has recently been reported to be a more specific test for detection of patients with IDH mutations than total 2-HG alone. 6 Digital PCR enables the quantitative identification of single-nucleotide variants (SNVs) against a wild-type DNA background. It relies on the random distribution of DNA molecules in multiple partitions of starting sample. Provided a sufficient number of partitions, and sufficient dilution to ensure that not every partition contains a target, Poisson statistics can estimate the number of SNV targets per partition in a binary manner, independent of exponential kinetics or reliance on standard curves. It has been made clinically practicable by the advent of nanofluidic and droplet-based partitioning platforms and has been applied to quantitate rare mutations in several cancers, including NPM1 mut AML 8 and ABL kinase domain mutations in chronic myeloid leukemia. 9 It is more sensitive than Sanger sequencing (which has a mutant allele frequency (MAF) detection threshold of~5-20%), and less burdensome and substantially cheaper than next-generation sequencing.
We assessed the D-2-HG:L-2-HG ratio in plasma samples collected from 192 consecutive patients presenting between February 2010 and December 2014 to The Christie NHS Foundation Trust in Manchester, UK, with newly diagnosed refractory cytopenia with multilineage dysplasia (RCMD; n = 21), refractory anemia with excess blasts (RAEB; n = 28) or AML (n = 116); or with relapsed AML (n = 27; Supplementary Figure S1 and Supplementary Table S1 ). In each case platelet-poor plasma and mononuclear cells from blood and/or bone marrow (BM) were cryopreserved at presentation and at frequent intervals thereafter. IDH mut cases were identified by Sanger sequencing of genomic DNA from presentation samples, with the exception of two cases where only blood mononuclear cells containing a low frequency of blasts were available for analysis. 5 In these cases digital PCR provided the diagnosis where Sanger sequencing was unable to. Presentation and follow-up plasma samples were blindly screened for 2-HG stereoisomers by ultra-performance liquid chromatography with tandem mass spectrometry (Supplementary Figure S2 ). 10 For digital PCR, we first designed and validated Taqman SNP genotyping quantitative PCR assays for the six most common IDH mutations (IDH1 R132C/G/H/S ; IDH2 R140Q/R172K ), comprising pooled common primers with FAM-and VIC-dye-labeled probes specific for each mutant or wild-type sequence, respectively ( Supplementary Figures S3-S5 ). Allelic discrimination quantitative PCR clearly and correctly distinguished IDH mut from IDH wt patients in all replicates from all cases for each assay (Supplementary Figure S5 ). We then used these validated quantitative PCR assays in a digital PCR protocol using a nanofluidic platform and 37 K integrated fluidic circuit chips (Fluidigm, San Francisco, CA, USA; Supplementary Information). Digital PCR assays provided excellent reproducibility between replicates throughout the MAF range (R 2 = 0.994; Supplementary Figures S6A and B) and were validated as quantitative to ⩽ 0.1% in spiking experiments (Supplementary Figure S7 ).
As expected, 6 the mean (± s.d.) plasma D-2-HG:L-2-HG ratio was significantly higher in IDH mut versus IDH wt patients (41.8 ±28.2; Figure 1a ), with a ratio ⩾ 1.93 identifying the 36 IDH mut cases at presentation with 100% sensitivity and 95% specificity ( Figure 1b ) and a ratio ⩾ 4.26 identifying IDH mut cases with a unique performance of 100% sensitivity and 100% specificity (Figure 1b) . The mean ± s.d. for plasma D-2-HG:L-2-HG ratio for IDH wt patients was 1.0 ± 0.58 (Figure 1a ). IDH mut frequencies for RCMD (2/21; 9.5%), RAEB (4/28; 14.3%) and AML (30/143; 21.0%) were also as expected. 11 For the comparison of enantiomeric ratio versus digital PCR, in addition to presentation samples from 36 IDH mut patients, there were follow-up serial plasma and cell samples available for 30 of these cases (median 7 samples per patient; range 2-20; median follow-up 27.6 months). Together, there were a total of 205 matched plasma and cellular genomic DNA pairs for analysis, spanning a wide range of mutant allele Accepted article preview online 19 June 2015; advance online publication, 14 July 2015 frequencies ( Figure 1c ) and clinical situations (Supplementary Figure S8A) , facilitating a detailed analysis. There was very strong correlation of the plasma D:L ratio with the MAFs determined from either blood or BM mononuclear cells (Spearman coefficients were ρ = 0.80 and 0.86 respectively; both P o 0.0001; Figure 1c ). Interestingly, the correlations of either D:L ratio or MAF with BM blast percentage, the traditional measure of disease burden, were substantially weaker (ρ = 0.68 and 0.64, respectively) in keeping with the presence of IDH mutations in cells other than myeloblasts both at diagnosis and during follow-up ( Supplementary Figures  S8B and C) . Importantly, at the lower ends of detection digital PCR demonstrated superior sensitivity compared with the D:L ratio (Figure 1c ). Although a D:L ratio ⩾ 1.8 identified all samples with MAF ⩾ 1%, this ratio only identified 37.5% (9/24) samples with MAFs 40.1% but o 1%. Thus, the sensitivity of the 2-HG enantiomeric ratio for detection of IDH-mutated clones drops substantially below a MAF of 1%, while digital PCR sensitivity is maintained to MAF levels of 0.1% (Figure 1b, Supplementary  Figure S7 ). This represents a level of sensitivity for digital PCR which is comparable to reported thresholds for multiparametric flow cytometry 12 and equivalent to next-generation sequencing at 41000-fold coverage. As expected, where paired contemporaneous blood and BM cell samples were available, IDH MAFs were typically lower in blood than BM samples (Supplementary Figure  S8D ). This indicates that optimal sensitivity for detection of IDHmutated cells is achieved by the analysis of BM cells versus blood mononuclear cells.
Indicative case histories illustrate the clinical significance of our observation that digital PCR is more sensitive in detecting lowlevel IDH mut allelic burden than the enantiomeric ratio. A patient with normal karyotype AML (BB235) was treated with intensive chemotherapy to complete remission (CR; Figure 2a ). The plasma D:L 2-HG ratio returned to a level indistinguishable from normal for 205 days following the start of the fourth course of chemotherapy. However, during this period on the two occasions for which data are available, persistence of an IDH1 R132H mutant allele was clearly detected, and this presaged a relapse that was successfully treated with allogeneic transplantation. A second patient with intermediate-risk AML (trisomy 8, FLT3 wt , NPM1 wt ) (BB187) similarly achieved CR following induction chemotherapy, together with normalization of the enantiomeric ratio and elimination of detectable IDH1 R132H mutant allele. In keeping with current shows receiver-operator characteristic curve for plasma D:L-2-HG ratio at presentation in IDH mut versus IDH wt patients (n = 192). Table (right  panel) shows sensitivity versus specificity at various threshold cutoffs. (c) Graph shows plasma D-2-HG:L-2-HG ratio versus MAF by digital PCR at matched time points (n = 205 combined presentation and follow-up time points from 36 patients). Green dots denote BM samples and brown squares, blood samples. Spearman correlation coefficients for enantiomeric ratio versus each mononuclear cell source are indicated.
risk-stratification protocols, this patient was consolidated with a sibling donor allogeneic transplant but subsequently died of graftversus-host disease (Figure 2b ). Future large-scale studies may provide evidence that rapid and complete clearance of mutant IDH predicts for patients who would fare better with chemotherapy alone. Other case histories demonstrate further the generally close correlation of morphologic disease, IDH mut allelic burden and an elevated D:L enantiomeric ratio (Supplementary Figure S9) .
We demonstrate here a feasible, robust and clinically applicable protocol for digital PCR for IDH mutations in myeloid malignancy, which delivers superior sensitivity to the 2-HG enantiomeric ratio at lower mutant allele frequencies. For monitoring of mutant IDH allele burdens of 41%, however, the enantiomeric ratio is equivalent to BM digital PCR and, by comparison with BM aspiration, significantly less invasive.
